Pfizer drug works in mild heart failure; Sanofi's Shantha buyout hasn't yet delivered;

@FiercePharma: Novartis teamed up with athletes for doctor marketing. Article | Follow @FiercePharma 

> Pfizer's diuretic Inspra can reduce deaths and hospitalizations for mild heart failure by 37 percent, researchers said Sunday, indicating that the drug or others in the class should be more widely used for treating the condition. News

> Sanofi-Aventis' €440 million ($602 million) acquisition of Indian vaccine maker Shantha Biotechnics failed to live up to analyst forecasts after manufacturing woes wiped out $340 million of sales. Report

> Vanda Pharmaceuticals said James Patrick Kelly will become its chief financial officer, treasurer, and secretary; most recently Kelly worked at MedImmune. Article

> Ranbaxy Laboratories sued AstraZeneca in the U.K. over claims that its European patents for the best-selling ulcer treatment Nexium are invalid, two years after settling a related U.S. case. Story

> British drugmaker ProStrakan said it was evaluating approaches for both the company and its assets after it rebuffed an offer from Dutch specialty group Norgine that it said undervalued the company. Item

> UCB fell the most in six months in Brussels trading after UBS recommended selling the shares, saying the drugmaker is unlikely to be acquired. Story

Biotech News 

 @FierceBiotech: Otsuka plots $2.8B IPO. News | Follow @FierceBiotech

> Benlysta review spooks investors ahead of FDA panel. News

> Lilly Ventures leads $24M round for Cerulean's Phase II. Report 

> Xarelto researchers wow analysts with blockbuster PhIII data. Story

> Sources: Genzyme floats $82 bid by Takeda. Article

Biotech IT News

> Young docs need greater ease of use in clinic IT tools. Story 

> Lilly CIO considers cloud for clinic data. Item 

> DATATRAK adds cross-trial reports to eClinical CTMS. News 

> Pfizer virtualizes to see acquisition's R&D data. Article 

> Social media key to clinic team recruiting. Report

> iTrials picks column database for subject recruitment. Story

And Finally... More bad news about post-menopausal hormone therapy: a new European study reports that women who take hormones face a significantly increased risk for ovarian cancer, which is rare but often fatal. Report